Doha Declaration: Compulsory Licensing and Access to Drugs

Authors

  • Ms. Kiran Kumari

  • Dr. Ajay Sharma

Keywords:

TRIPS, compulsory license, patent

Abstract

This paper analyses compulsory licensing evolution phases and sheds light on reasons behind development especially after trade related aspects of intellectual property rights (TRIPS) provisions. Without patents, the innovators can neither be adequately compensated for their costs of research nor be encouraged for further research to develop new and improved products. Patent protection is therefore accepted as a necessary evil, despite its conflict with the competitions laws and human rights law (in case of pharmaceutical patents). Prior to Doha declaration pharmaceutical companies were enjoying the monopoly right because of patent protection regime for manufacturing, sale, and import the products which result into high cost of the patented products. Doha Conference on November 14, 2001 forced many countries to amend their patent rights for the purpose of compulsory licensing. This increased cost on patented molecules was a major hindrance for access to medicine. Public health officials considered Doha Declaration on compulsory licensing a positive approach in prioritizing public health over intellectual property rights.

How to Cite

Doha Declaration: Compulsory Licensing and Access to Drugs. (2019). Global Journal of Medical Research, 19(10), 17-24. https://medicalresearchjournal.org/index.php/GJMR/article/view/1725

References

Rumman Ahmed, Amol Sharma (2012) Novartis Fights India for Cancer Pill Patent. https://www.wsj.com/articles/SB10000872396390444233104577594973786074692

H. Bale (1998) The conflicts between parallel trade and product access and innovation: The case of pharmaceuticals. Journal of Internationa. 1(4), 637-653. https://doi.org/10.1093/jiel/1.4.637

Bayer Corporation v (2014) Bayer Corporation v. Union of India.

Nilima Chandiramani (2002) Legal Factors in TRIPs. 8.

Harish Chander, Vaibhav Choudhary, Vikas Kumar (2013) Current Scenario of Patent Act: Compulsory Licensing. 47(3), 26-30. https://doi.org/10.5530/ijper.47.3.5

K. Christensen (2012) Gray Markets, Forbes India, Retrieved from: /gray-markets/32694/1 (). http://forbesindia.com/article/rotman/gray-markets/32694/1

David Cutler (2017) Empirical and Mathematical Reasoning: The Business and Politics of Health.

E., Durojaye (2011) compulsory licensing and access to medicines in post Doha Era: what hope for Africa?.

R. Gupta (2010) Compulsory Licensing under TRIPS: How afar it Addresses Public Health Concerns in Developing Nations. 15, 357-363.

T. Jain (2009) Compulsory licenses under trips and its obligations for member countries.

A. Kaur, R. Chaturvedi (2015) Compulsory Licensing of Drugs and Pharmaceuticals: Issues and Dilemma. 20, 279-287. http://docs.manupatra.in/newsline/articles/Upload/3FB94432-F6A8-44FD-8D4B-2EC49FABC703.pdf

K. Kulkarni, S. Mohanti (2013) Novartis loses landmark India cancer drug patent case. https://www.reuters.com/article/us-india-novartis-patent/novartis-loses-landmark-india-cancer-drug-patent-case-idUSBRE93002I20130401

S. Kumar (2013) Novartis Loses Historic India Patent Case on Cancer Drug Glivec. http://www.asianscientist.com/features/novartis-loses-historic-india-patentcase-cancer-drug-glivec-2013/

V. Mathur, B. Nagori, M. Tiwari (2016) Compulsory Licensing of Pharmaceutical Patents in India: A Research Study. 3(3), 532-543.

(2017) Madras High Court Judgement: Lee Pharma Limited vs. Lee Pharmaceuticals. https://indiankanoon.org/doc/187917013/

P. Narayanan (1998) Patent Law, third edition, Eastern Law House, p. 4.

R. Ayyangar (1959) Report on the Revision of the Patent Law.

S. Rana (2018) News. http://www.ssrana.in/

L. Taylor (2013) Novartis loses Indian Glivec patent case. http://www.pharmatimes.com/Article/13-04-02/

World Trade Organization Ministerial Conference (2001) Declaration on the TRIPS Agreement and Public Health. https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e

D. Yadav (2015) Spuriousdrugs/counterfeitdrugs- Anoverview. 3(10), 13-15. http://www.pharmatutor.org/taxonomy/term/2022

D. Yang (2012) Compulsory licensing: For better or for worse, the done deal lies in the balance. 17, 76-81.

Doha Declaration: Compulsory Licensing and Access to Drugs

Published

2019-03-25

How to Cite

Doha Declaration: Compulsory Licensing and Access to Drugs. (2019). Global Journal of Medical Research, 19(10), 17-24. https://medicalresearchjournal.org/index.php/GJMR/article/view/1725